romosozumab (Evenity) Report issue

Biologics mAb Approved FDA
AACT ChEMBL DrugBank MeSH

Active Ingredient History

NOW
  • Now
Romosozumab, sold under the brand name Evenity, is a medication used to treat osteoporosis. It has been found to decrease the risk of fractures of the spine.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$681.1350 - $916.9950
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

amg785 | amg 785 | amg-785 | cdp7851 | cdp 7851 | cdp-7851 | romosozumab

Organizations (15)

Research & Development (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (1)


 

Osteoporosis (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Alveolar Bone Loss (Phase 3)

Anorexia Nervosa (Phase 3)

Bone Diseases, Metabolic (Phase 3)

Feeding and Eating Disorders (Phase 3)

Fracture Healing (Phase 2)

Multiple Myeloma (Phase 1)

Osteogenesis Imperfecta (Phase 3)

Osteoporosis (Phase 4)

Osteoporosis, Postmenopausal (Phase 4)

Paralysis (Phase 2)

Postmenopause (Phase 1)

Spinal Cord Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 33
  • # of Trial Organizations: 15

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue